LSD Human Experimentation / Research Documentary Film
LSD Human Experimentation / Research Documentary Film – Experimental Compound MER 17 (Frenquel) and LSD-25: Psychosis. National Security Council. Central Intelligence Agency. (09/18/1947 – 12/04/1981). ARC Identifier 1634172 / Local Identifier 263.1057. This film examines human medical experiments to determine the efficacy of LSD-25 and MER 17 (Frenquel) on treating psychosis. Producer: National Archives and Records Administration. Creative Commons license: Public Domain Chemist Albert Hofmann, working at the Sandoz Corporation pharmaceutical laboratory in Switzerland, first synthesized LSD in 1938. He was conducting research on possible medical applications of various lysergic acid compounds derived from ergot, a fungus that develops on rye grass. Searching for compounds with therapeutic value, Hofmann created more than two dozen ergot-derived synthetic molecules. LSD is sold on the street in tablets, capsules, and occasionally in liquid form. It is an odorless and colorless substance with a slightly bitter taste that is usually ingested orally. It is often added to absorbent paper, such as blotter paper, and divided into small decorated squares, with each square representing one dose. CONTROL STATUS LSD is a Schedule I substance under the Controlled Substances Act. Schedule I drugs, which include heroin and MDMA, have a high potential for abuse and serve no legitimate medical purpose. Its two precursors lysergic acid and lysergic acid amide are both in Schedule III of the CSA. The LSD precursors ergotamine and ergonovine are …
In Which The Guttmacher Institute Continues to be Awful
Filed under: drug addiction treatment act 2000
Option 1: Either immediately upon abortion being legalized in the Federal District of Mexico, from 2006 to 2007, the abortion rate experienced an epic, up to 2000% decrease. This would be bizarre, given that, as Stanley Henshaw of the Guttmacher …
Read more on Patheos (blog)
Ross Silver on How to Find the Perfect Combo of Biotech Science and
Filed under: drug addiction treatment act 2000
Mainly, when we talk about life science companies, it's the maturity of the business or the maturity of the drug candidate pipeline that causes the valuation disparity. The other …. Was it because the stock entered the Russell 2000 Index? Could that …
Read more on Jutia Group